← Back to Search

Robotic Exoskeleton

Robot-Based Gait Training for Cerebral Palsy

N/A
Recruiting
Led By Arun Jayaraman, PT, PhD
Research Sponsored by Shirley Ryan AbilityLab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gross Motor Function Classification System score of 2-4
Height range of approximately 110cm to 170cm
Must not have
Critical motor control alterations such as dystonia, choreoathetosis, or ataxia
Unhealed wounds/lesions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline gait quality at 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if the CPWalker, a robotic device that supports and guides children with cerebral palsy, can help improve their walking ability. The goal is to see if these children can walk better after several training sessions. The CPWalker is a robotic device designed to support and guide children with cerebral palsy, and similar robotic systems have shown effectiveness in improving gait and quality of life in children with CP.

Who is the study for?
This trial is for children and young adults aged 11-21 with Cerebral Palsy, specifically spastic diplegia. They should weigh no more than 75kg, be between approximately 110cm to 170cm tall, and have a certain level of motor function (GMFCS score of 2-4). Participants must understand verbal instructions and fit the CPWalker's size requirements. Those with recent surgeries, ongoing botox treatments, severe deformities or cognitive impairments that prevent understanding exercises are excluded.
What is being tested?
The study is testing the CPWalker Robotic Exoskeleton as a walking aid for kids with Cerebral Palsy. It aims to see if this technology can help improve their ability to walk. The participants will use the robotic exoskeleton in gait training sessions to assess its effectiveness as an intervention tool.
What are the potential side effects?
Potential side effects may include discomfort from wearing the device, skin irritation where it touches the body, muscle fatigue due to exercise during therapy sessions, and possible pain if pre-existing conditions like unhealed wounds are aggravated.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk but with limitations.
Select...
My height is between 110cm and 170cm.
Select...
I am between 11 and 21 years old.
Select...
I can communicate my pain and follow simple instructions.
Select...
I have been diagnosed with Cerebral Palsy, specifically spastic diplegia.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have movement issues like uncontrolled movements or trouble with coordination.
Select...
I have wounds or lesions that have not healed.
Select...
I am able to understand instructions and interact with study staff.
Select...
I haven't had any bone surgery in the last 3 months or ongoing botox treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline gait speed at 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline gait speed at 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
10-Meter Walk Test
Secondary study objectives
6-Minute Walk Test
Child and Adolescent Scale of Participation
GAITRite Data Collection
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CPWalker Robotic-Assisted Gait TrainingExperimental Treatment1 Intervention
Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Cerebral Palsy (CP) aim to improve motor function and walking ability. Physical and occupational therapy help strengthen muscles and improve coordination through targeted exercises. Orthotic devices, such as braces and adaptive strollers, provide support and correct alignment to facilitate better movement. Pharmacologic interventions, including anticholinergics, benzodiazepines, and baclofen, reduce muscle spasticity and dystonia, enhancing mobility. Surgical options, like selective dorsal rhizotomy, decrease spasticity by cutting nerve fibers that contribute to muscle tightness. These treatments are crucial for CP patients as they enhance functional independence, reduce pain, and improve overall quality of life.
The Most Cited Original Articles in Brain Imaging of Children With Cerebral Palsy: A Bibliometric Analysis Between 1984 and 2019.

Find a Location

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor
208 Previous Clinical Trials
17,995 Total Patients Enrolled
6 Trials studying Cerebral Palsy
306 Patients Enrolled for Cerebral Palsy
Arun Jayaraman, PT, PhDPrincipal Investigator - Shirley Ryan AbilityLab
Shirley Ryan AbilityLab
23 Previous Clinical Trials
3,372 Total Patients Enrolled

Media Library

CPWalker (Robotic Exoskeleton) Clinical Trial Eligibility Overview. Trial Name: NCT03937700 — N/A
Cerebral Palsy Research Study Groups: CPWalker Robotic-Assisted Gait Training
Cerebral Palsy Clinical Trial 2023: CPWalker Highlights & Side Effects. Trial Name: NCT03937700 — N/A
CPWalker (Robotic Exoskeleton) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03937700 — N/A
~5 spots leftby Nov 2025